• Friday, February 2, 2018 @ 12:00 am

Addex Therapeutics (SIX: ADXN) announced today that the independent life science research company Van Leeuwenhoeck has issued an equity research note highlighting the value of the recent strategic partnership with Indivior PLC on GABAB PAM.

"The deal with Indivior is a great example of how Addex is delivering on its strategy to unlock the value within its portfolio of proprietary allosteric modulators through collaboration", commented Marcel Wijma, Chief Research Analyst at Van Leeuwenhoeck Institute.

Go to full analyst research report.

You may also be interested in